Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes
Obesity · 2023
DOI: 10.1002/oby.23677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, 2023. Verfasst von Ebaa Al-Ozairi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dasman Diabetes Institute, Kuwait City, Kuwait. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
This study evaluated whether adding sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) and/or glucagon‐like peptide‐1 receptor agonists (GLP1‐RA) to insulin reduced weight and glycemia in people with type 1 diabetes.
Methods
This retrospective analysis of electronic health records evaluated 296 people with type 1 diabetes over 12 months after medications were first prescribed. Four groups were defined: control n = 80, SGLT2i n = 94, GLP1‐RA n = 82, and combination of drugs (Combo) n = 40. We measured changes at 1 year in weight and glycated hemoglobin (HbA1c).
Results
The control group did not have changes in weight or glycemic control. The mean (SD) percentage weight loss after 12 months was 4.4% (6.0%), 8.2% (8.5%), and 9.0% (8.4%) in the SGLT2i, GLP1‐RA, and Combo groups, respectively ( p < 0.001). The Combo group lost the most weight ( p < 0.001). The HbA1c reduction was 0.4% (0.7%), 0.3% (0.7%), and 0.6% (0.8%) in the SGLT2i, GLP1‐RA, and Combo groups, respectively ( p < 0.001). The Combo group had the biggest improvements in glycemic control and total and low‐density lipoprotein cholesterol compared with baseline (all p < 0.01). Severe adverse events were similar between all the groups, with no increased risk of diabetic ketoacidosis.
Conclusions
The SGLT2i and GLP1‐RA agents on their own improved body weight and glycemia, but combining the medications resulted in more weight loss. Treatment intensification appears to result in benefits with no difference in severe adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dasman Diabetes Institute, Kuwait City, Kuwait.
- Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.
- Diabetes Complications Research Center, UCD Conway Institute, University College Dublin School of Medicine, Dublin, Ireland.
- Diabetes Research Centre, Ulster University, Coleraine, UK.
ORCID-Profile: Ebaa Al-Ozairi, Mohammad Irshad, Carel W le Roux
Zitieren
APA
Al-Ozairi, E., Irshad, M., Taghadom, E., Sojan, L., Al Kandari, J., Alroudhan, D., & le Roux, C. W. (2023). Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes. Obesity. https://doi.org/10.1002/oby.23677
Vancouver
Al-Ozairi E, Irshad M, Taghadom E, Sojan L, Al Kandari J, Alroudhan D, et al. Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes. Obesity. 2023. doi:10.1002/oby.23677
BibTeX
@article{AlOzairi2023,
author = {Al-Ozairi, Ebaa and Irshad, Mohammad and Taghadom, Etab and Sojan, Litty and Al Kandari, Jumana and Alroudhan, Dherar and le Roux, Carel W},
title = {Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes},
journal = {Obesity},
year = {2023},
doi = {10.1002/oby.23677}
}
EUVIMED